JOGC

Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer

        Breast cancer accounts for almost 25% of all cancers diagnosed in women (1.4 million cases worldwide survival differences can be attributed in part to early-detection programs and access to treatment, other factors in 2008), and it is clearly the greatest concern for women considering menopausal HT to ease their transition into menopause. The cumulative incidence of breast cancer among women in Europe and North America is about 2.7% by age 55, about 5.0% by age 65, and about 7.7% by age 75.
        • Key T.J.
        • Verkasalo P.K.
        • Banks E.
        Epidemiology of breast cancer.
        To read this article in full you will need to make a payment

        REFERENCES

          • Key T.J.
          • Verkasalo P.K.
          • Banks E.
          Epidemiology of breast cancer.
          Lancet Oncol. 2001; 2: 133-140
          • American Cancer Society
          Cancer facts & figures.
          American Cancer Society, Atlanta, Georgia2008 (Available at) (Accessed 2013 Aug 12)
          • Feinlieb M.
          Breast cancer and artificial menopause: a cohort study.
          J Natl Cancer Inst. 1968; 41: 315-329
          • Youlden D.R.
          • Cramb S.M.
          • Dunn N.A.
          • Muller J.M.
          • Pyke C.M.
          • Baade P.D.
          The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality.
          Cancer Epidemiol. 2012; 36: 237-248
          • Welch H.G.
          • Woloshin S.
          • Schwartz L.M.
          The sea of uncertainty surrounding ductal carcinoma in situ—the price of screening mammography.
          J Natl Cancer Inst. 2008; 100: 228-229
          • Peto R.
          • Davies C.
          • Godwin J.
          • Gray R.
          • Pan H.C.
          • Clarke M.
          • et al.
          Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
          Lancet. 2012; 379: 432-444
          • Colditz G.A.
          • Hankiinson S.E.
          • Hunter D.J.
          • Willett W.C.
          • Manson J.E.
          • Stampfer M.J.
          • et al.
          The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
          N Engl J Med. 1995; 332: 1589-1593
          • Collaborative Group on Hormonal Factors in Breast Cancer
          Breast cancer and hormone replacement therapy: a collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.
          Lancet. 1997; 350: 1047-1059
          • LaCroix A.Z.
          • Chlebowski R.T.
          • Manson J.E.
          • Aragaki A.K.
          • Johnson K.C.
          • Martin L.
          • et al.
          Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.
          JAMA. 2011; 305: 1305-1314
          • Stefanick M.L.
          • Anderson G.L.
          • Margolis K.L.
          • Hendrix S.L.
          • Rodabough R.J.
          • Paskett E.D.
          • Investigators W.H.I.
          • et al.
          Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
          JAMA. 2006; 295: 1647-1657
          • McTiernan A.
          • Chlebowski R.T.
          • Martin C.
          • Peck J.D.
          • Aragaki A.
          • Pisano E.D.
          • et al.
          Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women’s Health Initiative randomized trial.
          J Clin Oncol. 2009; 27: 6135-6143
          • McTiernan A.
          • Martin C.F.
          • Peck J.D.
          • Aragaki A.K.
          • Chlebowski R.T.
          • Pisano E.D.
          • Women’s Health Initiative Mammogram Density Study Investigators
          • et al.
          Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women’s Health Initiative Randomized Trial.
          J Natl Cancer Inst. 2005; 97: 1366-1376
          • Lyytinen H.
          • Pukkala E.
          • Ylikorkala O.
          Breast cancer risk in postmenopausal women using estrogen-only therapy.
          Obstet Gynecol. 2006; 108: 1354-1360
          • Zhang S.M.
          • Manson J.E.
          • Rexrode K.M.
          • Cook N.R.
          • Buring J.E.
          • Lee I.M.
          Use of oral conjugated estrogen alone and risk of breast cancer.
          Am J Epidemiol. 2006; 165: 524-529
          • Li C.I.
          • Malone K.E.
          • Porter P.L.
          • Weiss N.S.
          • Tang M.T.
          • Cushing-Haugen K.L.
          • et al.
          Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
          JAMA. 2003; 289: 3254-3263
          • Chlebowski R.T.
          • Anderson G.L.
          Changing concepts: menopausal hormone therapy and breast cancer.
          J Natl Cancer Inst. 2012; 104: 517-527
          • Fournier A.
          • Mesrine S.
          • Boutron-Ruault M.C.
          • Clavel-Chapelon C.
          Estrogen-progestagen menopausal hormone therapy and breast cancer: Does delay from menopause onset to treatment initiation influence risks?.
          J Clin Oncol. 2009; 27: 5138-5143
          • Beral V.
          • Reeves G.
          • Bull D.
          • Green J.
          • for the Million Women Study Collaborators
          Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
          J Natl Cancer Inst. 2011; 103: 296-305
          • Jordan V.C.
          • Ford L.G.
          Paradoxical clinical effect of estrogen on breast cancer risk: a new biology of estrogen induced apoptosis.
          Cancer Prev Res. 2011; 4: 633-637
          • Beral V.
          • for the Million Women Study Collaborators
          Breast cancer and hormone-replacement therapy in the Million Women Study.
          Lancet. 2003; 362: 419-427
          • Spratt J.S.
          • Meyer J.S.
          • Spratt J.A.
          Rates of growth of human solid neoplasms: part I.
          J Surg Oncol. 1995; 60: 137-146
          • Dietel M.
          • Lewis M.A.
          • Shapiro S.
          Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review.
          Hum Reprod. 2005; 20: 2052-2060
          • Speroff L.
          Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
          Menopause. 2008; 15: 393-400
          • Whitehead M.
          • Farmer R.
          The Million Women Study: a critique.
          Endocrine. 2004; 24: 187-193
          • Shapiro S.
          The Million Women Study: potential biases do not allow uncritical acceptance of the data.
          Climacteric. 2004; 7: 3-7
          • Bakken K.
          • Fournier A.
          • Lund E.
          • Waaseth M.
          • Dumeaux V.
          • Clavel-Chapelon F.
          • et al.
          Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. (EPIC Study).
          Int J Cancer. 2011; 128: 144-156
          • Reeves G.K.
          • Beral V.
          • Green J.
          • Gathani T.
          • Bull D.
          • for the Million Women Study Collaborators
          Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.
          Lancet Oncol. 2006; 7: 910-918
          • Opatrny L.
          • Dell’Aniello S.
          • Assouline S.
          • Suissa S.
          Hormone replacement therapy use and variations in the risk of breast cancer.
          BJOG. 2008; 115: 169-175
          • Boyd N.F.
          • Martin L.J.
          • Yaffe M.J.
          • Minkin S.
          Mammographic density: a hormonally responsive risk factor for breast cancer.
          J Br Menopause Soc. 2006; 12: 186-193
          • Tamimi R.M.
          • Byrne C.
          • Colditz G.A.
          • Hankinson S.E.
          Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
          J Natl Cancer Inst. 2007; 99: 1178-1187
          • Conner P.
          Breast response to menopausal hormone therapy—aspects on proliferation, apoptosis and mammographic density.
          Ann Med. 2007; 39: 28-41
          • McCormack V.A.
          • dos Santos Silva I.
          Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis.
          Cancer Epidemiol Biomarkers Prev. 2006; 15: 1159-1169
          • Nachtigall L.E.
          Breast density as a clinical entity: Is it a marker for breast cancer?.
          Menopause. 2007; 14: 345-346
          • Harvey J.
          • Scheurer C.
          • Kawakami F.T.
          • Quebe-Fehling E.
          • de Palacios P.I.
          • Ragavan V.V.
          Hormone replacement therapy and breast density changes.
          Climacteric. 2005; 8: 185-192
          • Grady D.
          • Vittinghoff E.
          • Lin F.
          • Hanes V.
          • Ensrud K.
          • Habel L.A.
          • et al.
          Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.
          Menopause. 2007; 14: 391-396
          • Corrao G.
          • Zambon A.
          • Conti V.
          • Nicotra F.
          • La Vecchia C.
          • Fornari C.
          • et al.
          Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation.
          Ann Oncol. 2008; 19: 150-155
          • Kerlikowske K.
          • Cook A.J.
          • Buist D.S.
          • Cummings S.R.
          • Vachon C.
          • Vacek P.
          • et al.
          Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
          J Clin Oncol. 2010; 28: 3830-3837
          • Moy L.
          • Slanetz P.J.
          • Yeh E.D.
          • Moore R.H.
          • Rafferty E.A.
          • Kopans D.B.
          Hormone replacement therapy rarely complicates or alters interpretation on screening mammography: a prospective analysis [abstract].
          Radiology. 2000; 217: 446
          • Carney P.A.
          • Miglioretti D.L.
          • Yankaskas B.C.
          • Kerlikowske K.
          • Rosenberg R.
          • Rutter C.M.
          • et al.
          Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography.
          Ann Intern Med. 2003; 138: 168-175
          • Laya M.B.
          • Larson E.B.
          • Taplin S.H.
          • White E.
          Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography.
          J Natl Cancer Inst. 1996; 8: 643-649
          • Rosenberg R.D.
          • Hunt W.C.
          • Williamson M.R.
          • Gilliland F.D.
          • Wiest P.W.
          • Kelsey C.A.
          • et al.
          Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico.
          Radiology. 1998; 209: 511-518
          • Litherland J.C.
          • Stallard S.
          • Hole D.
          • Cordiner C.
          The effect of hormone replacement therapy on the sensitivity of screening mammograms.
          Clin Radiol. 1999; 54: 285-288
          • Kavanagh A.M.
          • Mitchell H.
          • Giles G.G.
          Hormone replacement therapy and accuracy of mammographic screening.
          Lancet. 2000; 355: 270-274
          • Chlebowski R.T.
          • Hendrix S.L.
          • Langer R.D.
          • Stefanick M.L.
          • Gass M.
          • Lane D.
          • Investigators W.H.I.
          Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial.
          JAMA. 2003; 289: 3243-3253
          • Chlebowski R.T.
          • Anderson G.
          • Pettinger M.
          • Lane D.
          • Langer R.D.
          • for the Women’s Health Initiative Investigators
          • et al.
          Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.
          Arch Intern Med. 2008; 168: 370-377
          • Anderson G.L.
          • Chlebowski R.T.
          • Rossouw J.E.
          • Rodabough R.J.
          • McTiernan A.
          • Margolis K.L.
          • et al.
          Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomised trial of estrogen plus progestin.
          Maturitas. 2006; 55 (Epub 2006 Jul 11): 103-115
          • Seeger H.
          • Wallweiner D.
          • Mueck A.O.
          The effect of progesterone and synthetic progestins on serum and estradiol-stimultaed proliferation of human breast cancer cells.
          Horm Metab Res. 2003; 35: 76-80
          • Wood C.E.
          • Register T.C.
          • Lees C.J.
          • Chen H.
          • Kimrey S.
          • Cline J.M.
          Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
          Breast Cancer Res Treat. 2007; 101: 125-134
          • Murkes D.
          • Lalitkumar P.G.L.
          • Leifland K.
          • Lundström E.
          • Söderqvist G.
          Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
          Gynecol Endocrinol. 2012; 28 (Epub 2012 July 27): 12-15
          • Fournier A.
          • Berrino F.
          • Clavel-Chapelon F.
          Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.
          Breast Cancer Res Treat. 2008; 107: 103-111
          • Shapiro S.
          • Farmer R.D.
          • Mueck A.O.
          • Seaman H.
          • Stevenson J.C.
          Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 3. The Women’s Health Initiative: unopposed estrogen.
          J Fam Plann Reprod Health Care. 2011; 37: 225-230
          • Shapiro S.
          • Farmer R.D.
          • Mueck A.O.
          • Seaman H.
          • Stevenson J.C.
          Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 2. The Women’s Health Initiative: estrogen plus progestogen.
          J Fam Plann Reprod Health Care. 2011; 37: 165-172
          • Shapiro S.
          • Farmer R.D.
          • Seaman H.
          • Stevenson J.C.
          • Mueck A.O.
          Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 1. The Collaborative Reanalysis.
          J Fam Plann Reprod Health Care. 2011; 37: 103-109
          • Santen R.J.
          • Heitjan D.F.
          Modelling of growth kinetics of occult breast tumours: role in interpretation of studies of prevention and menopausal hormone therapy.
          Cancer Epidemiol Biomarkers Prev. 2012; 21: 1038-1048
          • Russo J.
          • Russo I.H.
          The role of estrogen in the initiation of breast cancer.
          J Steroid Biochem Mol Biol. 2006; 102: 89-96
          • Wren B.G.
          The origin of breast cancer.
          Menopause. 2007; 14: 1060-1068
          • Jemal A.
          • Ward E.
          • Thun M.J.
          Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
          Breast Cancer Res. 2007; 9: R28
          • Glass A.G.
          • Lacey Jr., J.V.
          • Carreon J.D.
          • Hoover R.N.
          Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
          J Natl Cancer Inst. 2007; 99 (Epub 2007 Jul 24): 1152-1161
          • Tarone R.E.
          • Chu K.C.
          Implications of birth cohort patterns in interpreting trends in breast cancer rates.
          J Natl Cancer Inst. 1992; 84: 1402-1410
          • Blot W.J.
          • Devesa S.S.
          • Fraumeni Jr., J.F.
          Declining breast cancer mortality among young American women.
          J Natl Cancer Inst. 1987; 78: 451-454
          • Collaborative Group on Hormonal Factors and Breast Cancer
          Breast cancer and breast feeding: collaborative reanalysis of data from 47 epidemiologic studies in 30 countries including 50, 302 women with breast cancer and 96, 973 women without the disease.
          Lancet. 2002; 360: 187-195
          • Kerlikowske K.
          • Miglioretti D.L.
          • Buist D.S.M.
          • Walker R.
          • Carney P.A.
          Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
          J Natl Cancer Inst. 2007; 99: 1335-1339
          • Li C.I.
          • Daling J.R.
          Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004.
          Cancer Epidemiol Biomarkers Prev. 2007; 16: 2773-2780
          • Gompel A.
          • Plu-Bureau G.
          Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy?.
          Ann N Y Acad Sci. 2010; 1205: 268-276
          • Shapiro S.
          • Farmer R.D.T.
          • Stevenson J.C.
          • Burger H.G.
          • Mueck A.O.
          • Gompel A.
          Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies: part 5. Trends in breast cancer incidence in relation to the use of HRT.
          J Fam Plann Reprod Health Care. 2013; 39: 80-88
          • Council for International Organizations of Medical Sciences
          Guidelines for preparing core clinical-safety information on drugs. 2nd ed. CIOMS, Geneva1999
          • Atkin C.K.
          • Smith S.W.
          • McFeters C.
          • Ferguson V.
          A comprehensive analysis of breast cancer news coverage in leading media outlets focusing on environmental risks and prevention.
          J Health Commun. 2008; 13: 3-19
          • Fletcher S.W.
          • Elmore J.G.
          Mammographic screening for breast cancer.
          N Engl J Med. 2003; 348: 1672-1680
          • Giordano S.H.
          • Hortobagyi G.N.
          Time to remove the subspecialty blinders: breast cancer does not exist in isolation.
          J Natl Cancer Inst. 2008; 100: 230-231
          • Chapman J.A.
          • Meng D.
          • Shepherd L.
          • Parulekar W.
          • Ingle J.N.
          • Muss H.B.
          • et al.
          Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
          J Natl Cancer Inst. 2008; 100: 252-260
          • Bluming A.Z.
          • Tavaris C.
          What are the real risks for breast cancer?.
          Climacteric. 2012; 15: 133-135
          • Singletary S.E.
          Rating the risk factors for breast cancer.
          Ann Surg. 2003; 4: 474-482
          • Reeves G.K.
          • Pirie K.
          • Beral V.
          • Green J.
          • Spencer E.
          • Bull D.
          Million Women Study Collaboration.
          Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007; 335 (Epub 2007 Nov 6): 1134
          • Prentice R.L.
          • Caan B.
          • Chlebowski R.T.
          • Patterson R.
          • Kuller L.H.
          • Ockene J.K.
          • et al.
          Low-fat dietary pattern and risk of invasive breast cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial.
          JAMA. 2006; 295: 629-642
          • Prentice R.L.
          • Thomson C.A.
          • Caan B.
          • Hubbell F.A.
          • Anderson G.L.
          • Beresford S.A.
          • et al.
          Low-fat dietary pattern and cancer incidence in the Women’s Health Initiative Dietary Modification Randomized Controlled Trial.
          J Natl Cancer Inst. 2007; 99: 1534-1543
          • Sprague B.L.
          • Trentham-Dietz A.
          • Egan K.M.
          • Titus-Ernstoff L.
          • Hampton J.M.
          • Newcomb P.A.
          Proportion of invasive breast cancer attributable to risk factors modifiable after menopause.
          Am J Epidemiol. 2008; 168: 404-411
          • Collins J.
          Hormones and breast cancer: Should practice be changed?.
          Obstet Gynecol. 2006; 108: 1352-1353
          • Brett K.M.
          • Reuben C.A.
          Prevalence of estrogen or estrogen–progestin hormone therapy use.
          Obstet Gynecol. 2003; 102: 1240-1249
          • Sellars T.A.
          • Mink P.J.
          • Cerhan J.R.
          • Zheng W.
          • Anderson K.E.
          • Kushi L.H.
          • et al.
          The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer.
          Ann Intern Med. 1997; 127: 973-980
          • Speroff L.
          Alternative therapies for postmenopausal women.
          Int J Fertil Womens Med. 2005; 50: 101-104
          • O’Meara E.S.
          • Rossing M.A.
          • Daling J.R.
          • Elmore J.G.
          • Barlow W.E.
          • Weiss N.S.
          Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.
          J Natl Cancer Inst. 2001; 93: 754-762
          • Col N.F.
          • Hirota L.K.
          • Orr R.K.
          • Erban J.K.
          • Wong J.B.
          • Lau J.
          Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.
          J Clin Oncol. 2001; 19: 2357-2363
          • Holmberg L.
          • Iversen O.E.
          • Rudenstam C.M.
          • Hammar M.
          • Kumpulainen E.
          • Jaskiewicz J.
          • HABITS Study Group
          • et al.
          Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
          J Natl Cancer Inst. 2008; 100: 475-482
          • Holmberg L.
          • Anderson H.
          HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer—Is it safe?), a randomised comparison: trial stopped.
          Lancet. 2004; 363: 453-455
          • von Schoultz E.
          • Rutqvist L.E.
          • Stockholm Breast Cancer Study Group
          Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial.
          J Natl Cancer Inst. 2005; 97: 533-535
          • Barrett-Connor E.
          • Mosca L.
          • Collins P.
          • Geiger M.J.
          • Grady D.
          • Kornitzer M.
          • Raloxifene Use for The Heart (RUTH) Trial Investigators
          • et al.
          Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
          N Engl J Med. 2006; 355: 125-137
          • Stefanick M.L.
          Risk–benefit profiles of raloxifene for women.
          N Engl J Med. 2006; 355: 190-192
          • Vogel V.G.
          • Costantino J.P.
          • Wickerham D.L.
          • Cronin W.M.
          • Cecchini R.S.
          • Atkins J.N.
          • et al.
          National Surgical Adjuvant Breast Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
          JAMA. 2006; 295: 2727-2741

        Linked Article

        • ERRATA
          Journal of Obstetrics and Gynaecology Canada Vol. 37Issue 6
          • In Brief
            Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, et al; SOGC Menopause and Osteoporosis Working Group. Managing menopause. SOGC Clinical Practice Guideline No. 311, September 2014. J Obstet Gynaecol Can 2014;36(9 Suppl 2):S33-S80.
          • Full-Text
          • PDF